Team:USTC CHINA/Parts

From 2013.igem.org

(Difference between revisions)
Line 1: Line 1:
 +
{{USTC-China/hidden}}
<html>
<html>
 +
<head>
 +
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/main.css?action=raw&ctype=text/css" />
 +
<link rel="stylesheet" type="text/css" href="https://2013.igem.org/Team:USTC_CHINA/pro.css?action=raw&ctype=text/css" />
<style type="text/css">
<style type="text/css">
-
/* hiding the top section*/
+
.part-col-1{float:left;width:290px;padding:10px;}
-
body{position:absolute; top:0px; width:100%; height:2480px;}
+
.part-col-2{float:left;width:145px;padding:5px;}
-
#top-section{
+
-
  height:0px;
+
-
    border:none;
+
-
    width:980px;
+
-
    margin:0 auto;
+
-
    padding:0 0 0 0;
+
-
    background-color:transparent;
+
-
    overflow:hide;
+
-
 
+
-
}
+
-
#p-logo{display:none;}
+
-
#search-controls{display:none;}
+
-
#top{display:none;}
+
-
.firstHeading{display:none;}
+
-
/* end of hiding the top section*/
+
-
 
+
-
/* global setting*/
+
-
#globalWrapper{position:absolute; top:0px;left:0px; width:100%; padding:0 0 0
+
-
 
+
-
0;margin:0 0 0 0;height:100%;}
+
-
#content{
+
-
    background-color:transparent;
+
-
    border:none;
+
-
    width:1200px;
+
-
    height:700px;
+
-
    marign:0 auto;
+
-
    padding:0 0 0 0;
+
-
    top:-40px;
+
-
    }
+
-
#bodyContent{
+
-
    background-color:transparent;
+
-
    border:none;
+
-
   
+
-
    }
+
-
siteSub{
+
-
    display:none;
+
-
    border:none;
+
-
    }
+
-
contentSub{
+
-
    display:none;
+
-
    }
+
-
/* end of global setting*/
+
-
 
+
-
/*hiding the footer-box*/
+
-
#footer-box{display:none;}
+
-
#catlinks{display:none;}
+
-
/*end of hiding the footer book*/
+
-
 
+
-
/* menu (page, edit ...) */
+
-
#menubar {
+
-
    background-color:transparent;
+
-
    position: relative;
+
-
    float:left;
+
-
    white-space: nowrap;
+
-
    top:-6px;
+
-
    width: 490px;
+
-
    z-index: 5000;
+
-
    font-family: sans-serif;
+
-
    font-size: 95%;
+
-
    line-height: 1em;
+
-
    z-index:99;
+
-
}
+
-
 
+
-
 
+
-
.left-menu, .left-menu a {
+
-
    text-align: left;
+
-
    color:#999999;
+
-
    text-transform: lowercase;
+
-
}
+
-
 
+
-
.left-menu:hover {
+
-
    color: #D00000;
+
-
    background-color: transparent;
+
-
}
+
-
 
+
-
.right-menu{width:400px; float:right}
+
-
.right-menu, .right-menu a {
+
-
    right: 0px;
+
-
    text-align: right;
+
-
    color: #999999;
+
-
}
+
-
#menubar ul {
+
-
    color: #999999;
+
-
    list-style: none;
+
-
}
+
-
#menubar li {
+
-
    display: inline;
+
-
    position: relative;
+
-
    cursor: pointer;
+
-
    padding-left: 0px;
+
-
    padding-right: 0px;
+
-
}
+
-
.left-menu li a {
+
-
    padding: 0px 10px 0px 0px;
+
-
}
+
-
.left-menu .selected {
+
-
#    color: #999999;
+
-
}
+
-
#.left-menu .selected:hover {
+
-
#    color: #999999;
+
-
#}
+
-
 
+
-
.left-menu:hover a {
+
-
    color: #999999;;
+
-
}
+
-
 
+
-
.left-menu li a:hover {
+
-
    color: #D00000;
+
-
    text-decoration: underline;
+
-
}
+
-
 
+
-
 
+
-
.right-menu li {
+
-
#    background-color: transparent;
+
-
}
+
-
.right-menu li a {
+
-
    padding: 0px 15px 0px 0px;
+
-
    color: #999999;;
+
-
    background-color: transparent;
+
-
}
+
-
.right-menu li a:hover {
+
-
    color: #D00000;
+
-
    text-decoration: underline;
+
-
}
+
-
/* end menu (edit, page ...) */
+
-
 
+
-
/* navigation bar*/
+
-
 
+
-
#navigationblock{background-color:#fafaf8; position:fixed; top:0px;
+
-
 
+
-
width:1200px; height:130px; overflow:hidden; font-family:Calibri, Arial;
+
-
 
+
-
float:left; margin:0px; padding:0px; z-index:1000; border-bottom:1px solid
+
-
 
+
-
#d3d7d8;}
+
-
#navbarlogo{position:absolute; top:0px; left:0px; width:1200px}
+
-
#navigationbar{position:absolute; left:460px; top:38px; font-size:16px; font-
+
-
 
+
-
weight:100; color:black;}
+
-
#navigationbar > li {display:block; list-style-type:none; float:left;
+
-
 
+
-
width:75px; height:30px; text-align:center; }
+
-
 
+
-
.Navbar_Item{background-color:transparent;}
+
-
.Navbar_Item a {color:black; text-decoration:none;}
+
-
.Navbar_Item > ul {display:none; width:900px; height:80px; text-align:center;
+
-
 
+
-
color:black; z-index:1100; }
+
-
.Navbar_Item > ul > li {float:left; list-style:none; text-align:center;
+
-
 
+
-
background-color:transparent; position:relative; top:10px; padding:0 10px;}
+
-
.Navbar_Item:hover{ border-bottom:1px solid #D00000; color:#D00000;
+
-
 
+
-
background-color:#fafaf8;}
+
-
.Navbar_Item:hover > ul{ display:block;}
+
-
.Navbar_Item:hover >a {color:#D00000; background-color:#fafaf8;}
+
-
.Navbar_Item > ul > li:hover {border-bottom:1px solid #D00000; color:#D00000;
+
-
 
+
-
background-color:#fafaf8;}
+
-
.Navbar_Item > ul > li:hover >a {color:#D00000}
+
-
 
+
-
 
+
-
#Home_Sublist{position:relative; top:0px; left:-50px;}
+
-
#Team_Sublist{position:relative; top:0px; left:-110px;}
+
-
#Project_Sublist{position:relative; top:0px; left:-180px;}
+
-
#Model_Sublist{position:relative; top:0px; left:-140px;}
+
-
#DataPage_Sublist{position:relative; top:0px; left:-60px;}
+
-
#Safety_Sublist{position:relative; top:0px; left:-180px;}
+
-
#HumanPractice_Sublist{position:relative; top:0px; left:-360px;}
+
-
 
+
-
#iGEM_logo{position:absolute; top:30px; left:1090px; height:80px;}
+
-
/*end navigation bar*/
+
-
/*Major body*/
+
-
#MajorBody{position:absolute; top:24px; left:0px; width:1200px; height:340px;
+
-
 
+
-
background-color:#f9f9f7;}
+
-
#LeftNavigation{position:fixed; top:130px; float:left; width:200px;
+
-
 
+
-
height:100%; background-color:#313131;z-index:1000;}
+
-
#ProjectListTitle{position:absolute; top:60px; left:20px; color:#ffffff; font-
+
-
 
+
-
family: calibri, arial, helvetica, sans-serif; border-bottom:0px}
+
-
#ProjectList{position:absolute; top:120px; left:5px; color:#ffffff; font-
+
-
 
+
-
family: calibri, arial, helvetica, sans-serif;}
+
-
#ProjectList > li {display:block; list-style-type:none; width:180px;
+
-
 
+
-
height:30px; font-size:20px; text-align:left; background-color:transparent;}
+
-
#ProjectList a {color:#ffffff; text-decoration:none; line-height:30px;}
+
-
 
+
-
 
+
-
 
+
-
 
+
-
#ModelOverviewContainer{position:absolute; top:130px; left:200px; width:1000px;
+
-
 
+
-
height:210px;}
+
-
#ModelOverviewBackground{position:absolute; top:0px; top:0px;}
+
-
#ModelOverviewTitle{position:absolute;  left:0px; top:50px; width:1000px; 
+
-
 
+
-
border-bottom:0px; color:#FFFFFF; font-size:48px; font-family:calibri,Arial,
+
-
 
+
-
Helvetica, sans-serif;line-height:60px; text-align:center;}
+
-
#MoedlOverviewIntroduction{position:absolute; left:60px; top:55px; border-
+
-
 
+
-
bottom:0px; color:#FFFFFF; font-size:25px; font-family:calibri,Arial,
+
-
 
+
-
Helvetica, sans-serif;line-height:60px; text-align:center;}
+
-
#ModelOverviewContent{position:absolute; top:100px; left:60px; width:700px;
+
-
 
+
-
height:400px;color:#FFFFFF;  font-size:18px;font-family:calibri,Arial,
+
-
 
+
-
Helvetica, sans-serif; text-align:justify; line-height:30px;}
+
-
 
+
-
 
+
-
 
+
-
/*Parts Editing Area*/
+
-
#PartsEditingArea{position:absolute; left:200px; top:340px; width:1000px;
+
-
 
+
-
height:3000px; background-color:#ffffff; padding:60px 0;}
+
-
 
+
-
#PartsEditingArea a{color:#5cc33c}
+
-
.SmallBoxs{position:absolute; width:400px; height:300px; background-
+
-
 
+
-
color:#eeeeee;}
+
-
#FavoritePart1{top:150px; left:80px;}
+
-
#FavoritePart2{top:150px; left:520px;}
+
-
#FavoritePart3{top:490px; left:80px;}
+
-
#FavoritePart4{top:490px; left:520px;}
+
-
#FavoritePart5{top:490px; left:80px;}
+
-
#FavoritePart6{top:490px; left:520px;}
+
-
 
+
-
#ImprovedPart{position:absolute;top:890px; left:80px; width:840px;
+
-
 
+
-
height:300px; background-color:#e5e5e5;}
+
-
 
+
-
#OtherPart{position:absolute;top:1290px; left:80px; width:840px; height:1500px;
+
-
 
+
-
background-color:#e5e5e5;}
+
-
#Dataplot{position:absolute;top:2900px; left:80px; width:840px; height:0px;
+
-
 
+
-
background-color:white;}
+
-
 
+
-
 
+
-
#Title1{position: absolute; top:70px; left:80px; width:200px; background-
+
-
 
+
-
color:#5cc33c;font-size:25px; font-family:calibri,Arial, Helvetica, sans-
+
-
 
+
-
serif;line-height:40px; text-align:center; font-weight:bold; font-
+
-
 
+
-
style:Italic;height:60px;color:#ffffff;}
+
-
#Title2{position: absolute; top:810px; left:80px; width:200px; background-
+
-
 
+
-
color:#5cc33c;font-size:25px; font-family:calibri,Arial, Helvetica, sans-
+
-
 
+
-
serif;line-height:40px; text-align:center;font-weight:bold; font-
+
-
 
+
-
style:Italic;height:60px;color:#ffffff;}
+
-
#Title3{position: absolute; top:1210px; left:80px; width:200px; background-
+
-
 
+
-
color:#5cc33c;font-size:25px; font-family:calibri,Arial, Helvetica, sans-
+
-
 
+
-
serif;line-height:40px; text-align:center; font-weight:bold; font-
+
-
 
+
-
style:Italic;height:60px;color:#ffffff;}
+
-
#Title4{position: absolute; top:2810px; left:80px; width:200px; background-
+
-
 
+
-
color:#5cc33c;font-size:25px; font-family:calibri,Arial, Helvetica, sans-
+
-
 
+
-
serif;line-height:40px; text-align:center; font-weight:bold; font-
+
-
 
+
-
style:Italic;height:60px;color:#ffffff;}
+
-
/*End of Parts Editing Area*/
+
-
 
+
-
 
+
-
 
+
-
/*end of Major body*/
+
-
#AcknowledgementBox{ position:absolute; left:0px; top:590px;
+
-
 
+
-
width:1200px;display:none;}
+
-
 
+
-
 
+
</style>
</style>
 +
</head>
 +
<body background="https://static.igem.org/mediawiki/2013/6/62/2013ustc-china_Light_grey_bg.png">
 +
<div class="bar" align="center">
 +
    <div class="container" align="left">
 +
<div id="igemlogo"><a href="https://2013.igem.org/Main_Page" target="_blank"><img src="https://static.igem.org/mediawiki/2013/2/26/2013ustcigem_IGEM_basic_Logo.png" alt="igem home page" width="50" height="40" /></a></div>
 +
<ul id="nav">
 +
        <li><a href="https://2013.igem.org/Team:USTC_CHINA">Home</a></li>
 +
        <li class="active"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Project</a>
 +
            <ul class="subs">
 +
                <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></li>
 +
                <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails">Project Details</a></li>
 +
                <li><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></li>
 +
                <li><a href="https://2013.igem.org/Team:USTC_CHINA/Parts">Parts</a></li>
 +
            </ul>
 +
        </li>
 +
        <li><a href="https://2013.igem.org/Team:USTC_CHINA/Notebook">Notebook</a>
 +
              <ul class="subs">
 +
                <li><a href="https://2013.igem.org/Team:USTC_CHINA/Notebook/Timeline">Timeline</a></li>
 +
                <li><a href="https://2013.igem.org/Team:USTC_CHINA/Notebook/Protocols">Protocols</a></li>
 +
              </ul>
 +
        </li>
 +
        <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/">Modeling</a>
 +
              <ul class="subs">
 +
                  <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/KillSwitch">Kill Switch</a></li>
 +
                  <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/B.SubtilisCulture">B.Subtilis Culture</a></li>
 +
                  <li><a href="https://2013.igem.org/Team:USTC_CHINA/Modeling/DesignsofImmuneExperiments">Designs of Immune Experiments</a></li>
 +
              </ul>
 +
        </li>
 +
        <li><a href="https://2013.igem.org/Team:USTC_CHINA/HumanPractice">Human Practice</a>
 +
              <ul class="subs">
 +
                  <li><a href="https://2013.igem.org/Team:USTC_CHINA/HumanPractice/Communication" >Communication</a></li>
 +
                  <li><a href="https://2013.igem.org/Team:USTC_CHINA/HumanPractice/Activity">Activity</a></li>
 +
              </ul>
 +
        </li>
 +
        <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team">Team</a>
 +
              <ul class="subs">
 +
                  <li><a href="https://2013.igem.org/Team:USTC_CHINA/Team">Members</a></li>
 +
                  <li><a href="https://igem.org/Team.cgi?year=2013&team_name=USTC_CHINA">Profile</a></li>
 +
                  <li><a href="https://2013.igem.org/Team:USTC_CHINA/Attributions">Attributions</a></li>
 +
                  <li><a href="https://igem.org/2013_Judging_Form?id=1074#iGEM_Medals">Achievements</a></li>
 +
              </ul>
 +
        </li>
 +
        <li><a href="https://2013.igem.org/Team:USTC_CHINA/Safety">Safety</a></li>
 +
    </ul>
 +
        <div id="tlogo"><img src="https://static.igem.org/mediawiki/2013/f/f8/2013ustc-china_T-VACCINE.png" width="100%" height="123" />
 +
        </div>
 +
        </div>
 +
        </div>
-
<!--navigationbar-->
+
<div class="content" align="center">
 +
<div class="conbar1">
 +
<div id="breadcrumb"><a href="https://2013.igem.org/Team:USTC_CHINA">Home</a> &gt; <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Project</a> &gt; <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div></div>
 +
<div class="conbar2">
 +
<div class="leftbar" align="left">
 +
        <div class="part-col-1">
 +
        <h1>TD1, Transdermal peptide</h1>
 +
        <h2><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1074000">BBa_K1074000</a></h2>
 +
        <p>TD1 is a short synthetic peptide(ACSSSPSKHCG)identified by in vivo phage display, facilitated efficient transdermal protein delivery through intact skin. Studies suggested that the peptide creates a transient opening in the skin barrier to enable macromolecular material to reach systemic circulation.</p>
 +
</div>
 +
<div class="part-col-1">
 +
        <h1>Pgrac+RBS+SamyQ+TD1+GFP</h1>
 +
        <h2><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1074006">BBa_K1074006</a></h2>
 +
        <p>This is the main circuit of our project to allow high expression of target protein(antigen,adjuvant).GFP can be substituted by various proteins via a modular PCR or standard cut/ligation method.</p>
 +
</div>
-
+
<div class="part-col-2">
-
</ul>
+
        <h1>Overview</h1>
-
         <a href="https://igem.org/Team_Wikis?year=2013"><img id="iGEM_logo"
+
         <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
-
src="https://static.igem.org/mediawiki/igem.org/4/48/Peking_igemlogo.jpg"/></a>
+
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
</div>
</div>
-
<!--end navigationbar-->
 
-
 
-
<!--MajorBody-->
 
-
<div id="MajorBody"> 
 
-
    </div>
 
-
    <div id="ModelOverviewContainer">
 
-
          <img id="ModelOverviewBackground"
 
-
 
-
src="https://static.igem.org/mediawiki/igem.org/a/a4/Peking2013_Datapage_background.jpg" />
 
-
          <h1 id="ModelOverviewTitle">Parts</h1>
 
-
          <h1 id="MoedlOverviewIntroduction"></h1>
 
-
          <p id="ModelOverviewContent"><br/>
 
-
 
-
</p>
 
-
    </div>
 
-
 
-
 
-
<!--parts editing area-->
 
-
<div id="PartsEditingArea">
 
-
 
-
    <div id="FavoritePart1" class="SmallBoxs">
 
-
<p id="Favoritecontent1" style="position:absolute; top:20px; width:360px;
 
-
 
-
left:20px;font-size:18px; font-family:calibri,Arial, Helvetica, sans-serif;
 
-
 
-
text-align:justify; line-height:25px;"><b>TD1, Transdermal peptide</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1074000">Main Page-BBa_K1074000</a>
 
-
</br>TD1 is a short synthetic peptide(ACSSSPSKHCG)identified by in vivo phage
 
-
 
-
display, facilitated efficient transdermal protein delivery through intact
 
-
 
-
skin. Studies suggested that the peptide creates a transient opening in the
 
-
 
-
skin barrier to enable macromolecular material to reach systemic circulation
 
-
</br>
 
-
 
-
</p>
 
-
    </div>
 
-
    <div id="FavoritePart2" class="SmallBoxs">
 
-
<p id="Favoritecontent2" style="position:absolute; top:20px; width:360px;
 
-
 
-
left:20px;font-size:18px; font-family:calibri,Arial, Helvetica, sans-serif;
 
-
 
-
text-align:justify; line-height:25px;"><b>Pgrac+RBS+SamyQ+TD1+GFP</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1074006">Main Page-BBa_K1074006</a>
 
-
This is the main circuit of our project to allow high expression of target
 
-
 
-
protein(antigen,adjuvant).GFP can be substituted by various proteins via a
 
-
 
-
modular PCR or standard cut/ligation method.
 
-
</br>
 
-
 
-
</p>
 
-
    </div>
 
-
    <div id="FavoritePart3" class="SmallBoxs">
 
-
<p id="Favoritecontent3" style="position:absolute; top:20px; width:360px;
 
-
 
-
left:20px; font-size:18px;font-family:calibri,Arial, Helvetica, sans-serif;
 
-
 
-
text-align:justify; line-height:25px;"><b>PHT43</b></br>
 
-
PHT43 is a E.coli-B.subtilis shuttle vector allowing high-level expression of
 
-
 
-
secreted proteins in B.subtilis. It is based on the strong σA-dependent
 
-
 
-
promoter preceding the groE operon of B. subtilis which has been converted into
 
-
 
-
an efficiently controllable (IPTGinducible)promoter by addition of the lac
 
-
 
-
operator. An efficient Shine-Dalgarno (SD) sequence as well as a multiple
 
-
 
-
cloning site (BamH I, Xba I, Aat II, Sma I) were also inserted. To obtain
 
-
 
-
secretion of recombinant proteins, the coding region for the signal peptide of
 
-
 
-
the amyQ gene encoding an α-amylase was fused to the SD sequence.
 
-
</br>
 
-
 
-
</p>
 
-
    </div>
 
-
    <div id="FavoritePart4" class="SmallBoxs">
 
-
<p id="Favoritecontent4" style="position:absolute; top:20px; width:360px;
 
-
 
-
left:20px; font-size:18px; font-family:calibri,Arial, Helvetica, sans-serif;
 
-
 
-
text-align:justify; line-height:25px;"><b>HBsAg</b></br>
 
-
HBsAg is the surface antigen of the hepatitis B virus (HBV). It indicates
 
-
 
-
current hepatitis B infection.
 
-
Sequence and Features
 
-
</br>
 
-
 
-
</p>
 
-
    </div>
 
-
 
-
 
-
 
-
 
-
 
-
<div id="OtherPart">
 
-
<p id="Summary1" style="position:relative; left:20px; font-size: 25px; font-
 
-
 
-
family:calibri,Arial, Helvetica, sans-serif;line-height:40px;" >
 
-
<b>Parts for Biosensors</b>
 
-
</p>
 
-
<p style="position: relative; top:0px; left: 20px; width:800px;  font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"><b>DmpR</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031221">BBa_K1031221</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031222">BBa_K1031222</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031223">BBa_K1031223</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031224">BBa_K1031224</a> are the
 
-
 
-
RBS library of DmpR biosensor's reporter. </br>
 
-
</p>
 
-
<p style="position: relative; top:20px; left: 20px; width:800px;  font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"><b>HbpR</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031300">BBa_K1031300</a> is the
 
-
 
-
coding sequence of HbpR with terminators. </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031301">BBa_K1031301</a> and
 
-
<a href="http://partsregistry.org/Part:BBa_K1031302">BBa_K1031302</a> are the
 
-
 
-
RBS library of HbpR biosensor's reporter. </br>
 
-
</p>
 
-
<p style="position: relative; top:40px; left: 20px; width:800px;  font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"><b>HcaR</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031410">BBa_K1031410</a> is the
 
-
 
-
coding sequence of HcaR with terminators. </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031441">BBa_K1031441</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031442">BBa_K1031442</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031443">BBa_K1031443</a> and
 
-
<a href="http://partsregistry.org/Part:BBa_K1031444">BBa_K1031444</a> are the
 
-
 
-
Pc library of HbpR to tune its performance . </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031420">BBa_K1031420</a> and
 
-
<a href="http://partsregistry.org/Part:BBa_K1031421">BBa_K1031421</a> are the
 
-
 
-
RBS library of HcaR biosensor's reporter. </br>
 
-
 
-
</p>
 
-
<p style="position: relative; top:50px; left: 20px; width:800px; font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"><b>CapR</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031100">BBa_K1031100</a> is the
 
-
 
-
coding sequence of CapR transcriptional factor. </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031111">BBa_K1031111</a> and     
 
-
 
-
   
 
-
<a href="http://partsregistry.org/Part:BBa_K1031112">BBa_K1031112</a> are basic
 
-
 
-
sensor construction with different CapR expression level.  </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031113">BBa_K1031113</a> and
 
-
<a href="http://partsregistry.org/Part:BBa_K1031114">BBa_K1031114</a> are
 
-
 
-
reporters with different RBS for the CapR biosensor. </br>
 
-
</p>
 
-
 
-
<p style="position: relative; top:60px; left: 20px; width:800px; font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"><b>HpaR</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031510">BBa_K1031510</a> is the
 
-
 
-
coding sequence of HpaR transcriptional factor. </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031520">BBa_K1031520</a> and     
 
-
 
-
   
 
-
<a href="http://partsregistry.org/Part:BBa_K1031521">BBa_K1031521</a> are
 
-
 
-
reporters with different RBS for the HpaR biosensor. </br>
 
-
</p>
 
-
 
-
<p style="position: relative; top:70px; left: 20px; width:800px; font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"><b>NahR</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031610">BBa_K1031610</a> is the
 
-
 
-
NahR biosensor circuit.</br>
 
-
</p>
 
-
 
-
<p style="position: relative; top:80px; left: 20px; width:800px;  font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"><b>PaaX</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031710">BBa_K1031710</a> is the
 
-
 
-
coding sequence of PaaX with terminators. </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031742">BBa_K1031742</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031743">BBa_K1031743</a> and
 
-
<a href="http://partsregistry.org/Part:BBa_K1031744">BBa_K1031744</a> are the
 
-
 
-
Pc library of PaaX. </br>
 
-
</p>
 
-
 
-
<p style="position: relative; top:90px; left: 20px; width:800px; font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"><b>XylS</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031911">BBa_K1031911</a> is the
 
-
 
-
coding sequence of XylS transcriptional factor with terminators. </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031912">BBa_K1031912</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031913">BBa_K1031913</a> and     
 
-
 
-
   
 
-
<a href="http://partsregistry.org/Part:BBa_K1031916">BBa_K1031916</a> are the
 
-
 
-
Pc library of XylS. </br>
 
-
</p>
 
-
 
-
<p style="position: relative; top:100px; left: 20px; width:800px;  font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"><b>XylR</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031803">BBa_K1031803</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031804">BBa_K1031804</a> are the
 
-
 
-
RBS library of XylR biosensor's reporter. </br>
 
-
</p>
 
-
 
-
 
-
<p id="Summary2" style="position:relative; top:120px; left:20px; font-size:
 
-
 
-
25px; font-family:calibri,Arial, Helvetica, sans-serif;line-height:40px;" >
 
-
<b>Parts for Adaptors</b>
 
-
 
-
<p style="position: relative; top:110px; left: 20px; width:800px; font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"><b>NahF</b></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031620">BBa_K1031620</a> is the
 
-
 
-
coding sequence of XylS transcriptional factor with terminators. </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031621">BBa_K1031621</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031622">BBa_K1031622</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031623">BBa_K1031623</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031624">BBa_K1031624</a> and     
 
-
 
-
   
 
-
<a href="http://partsregistry.org/Part:BBa_K1031625">BBa_K1031625</a>are the
 
-
 
-
Pc library of NahF. </br>
 
-
</p>
 
-
 
-
<p id="Summary3" style="position:relative; top:120px; left:20px; font-size:
 
-
 
-
25px; font-family:calibri,Arial, Helvetica, sans-serif;line-height:40px;" >
 
-
<b>Parts for Band-Pass Filter</b>
 
-
<p style="position: relative; top:90px; left: 20px; width:800px; font-
 
-
 
-
size:18px;font-family:calibri,Arial, Helvetica, sans-serif; text-align:justify;
 
-
 
-
line-height:30px;"></br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031021">BBa_K1031021</a> is the
 
-
 
-
hybrid promoter for the reporter node, which can be activated as well as
 
-
 
-
inhibited. </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031011">BBa_K1031011</a> is the
 
-
 
-
transcriptional factor that can activate its cognate promoter, which is used as
 
-
 
-
the activate node in the band-pass filter. </br>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031013">BBa_K1031013</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031014">BBa_K1031014</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031015">BBa_K1031015</a>
 
-
<a href="http://partsregistry.org/Part:BBa_K1031016">BBa_K1031016</a> are RBS
 
-
 
-
library to tune the expression of C1, under the control of pSal promoter, which
 
-
 
-
is a crucial part for band-pass filter. </br>
 
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
</div>
</div>
-
 
+
<div class="part-col-2">
-
 
+
        <h1>Overview</h1>
-
<div id="Title1">
+
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
-
<p>Favorite Parts</p>
+
</div>
</div>
-
<div id="Title2">
+
<div class="part-col-2">
-
<p>Improved Parts</p>
+
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
</div>
</div>
-
<div id="Title3">
+
<div class="part-col-2">
-
<p>Part List</p>
+
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
 +
</div>
 +
<div class="part-col-2">
 +
        <h1>Overview</h1>
 +
        <p>In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries. </p>
</div>
</div>
</div>
</div>
-
<!--end of parts editing area-->
+
<div class="rightbar">
-
 
+
<div class="port-sidebar-border"><h>Project</h></div>
-
 
+
<div class="clear"></div>
-
 
+
<div id="t1"><a class="active" href="https://2013.igem.org/Team:USTC_CHINA/Project/Overview">Overview</a></div>
-
+
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails">Project Details</a></div>
-
</div><!--end of major body-->
+
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Background">Background</a></div>
-
<img id="AcknowledgementBox"  
+
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">Design</a></div>
-
 
+
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Results</a></div>
-
src="https://static.igem.org/mediawiki/igem.org/c/c4/Peking_Sponsors.jpg">
+
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">Basic Experiment</a></div>
-
<!--end of acknowledgement box-->
+
<div id="t2"><a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results/FurthurWork">Furthur Work</a></div>
-
 
+
<div id="t1"><a href="https://2013.igem.org/Team:USTC_CHINA/Parts">Parts</a></div>
-
<script type="text/javascript"  
+
</div></div></div>       
-
 
+
       
-
src="http://ajax.googleapis.com/ajax/libs/jquery/1.8.0/jquery.min.js"></script>
+
</body>
-
<script type="text/javascript">
+
-
$(window).scroll(function(){
+
-
  if(0==document.getElementById("content").offsetLeft){
+
-
 
+
-
$('#navigationblock').css('left',-$(window).scrollLeft());}
+
-
  else{$('#navigationblock').css('left',document.getElementById
+
-
 
+
-
("content").offsetLeft); }
+
-
});
+
-
 
+
-
$(window).resize(function(){
+
-
  if(0==document.getElementById("content").offsetLeft){
+
-
 
+
-
$('#navigationblock').css('left',-$(window).scrollLeft());}
+
-
  else{$('#navigationblock').css('left',document.getElementById
+
-
 
+
-
("content").offsetLeft); }
+
-
});
+
-
 
+
-
 
+
-
function MoveInSlide(SlideId)
+
-
{
+
-
$(SlideId).animate({top:"0px"});
+
-
         
+
-
};
+
-
 
+
-
function MoveOutSlide(SlideId)
+
-
{
+
-
$(SlideId).animate({top:"280px"});
+
-
       
+
-
};
+
-
 
+
-
 
+
-
</script>
+
-
 
+
</html>
</html>

Revision as of 13:13, 27 September 2013

TD1, Transdermal peptide

BBa_K1074000

TD1 is a short synthetic peptide(ACSSSPSKHCG)identified by in vivo phage display, facilitated efficient transdermal protein delivery through intact skin. Studies suggested that the peptide creates a transient opening in the skin barrier to enable macromolecular material to reach systemic circulation.

Pgrac+RBS+SamyQ+TD1+GFP

BBa_K1074006

This is the main circuit of our project to allow high expression of target protein(antigen,adjuvant).GFP can be substituted by various proteins via a modular PCR or standard cut/ligation method.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Overview

In our world, billions of people suffer from contagion, however, only part of them can be prevented by proper vaccine. Many disadvantages limit the usage of traditional vaccine especially in developing countries.

Project

Retrieved from "http://2013.igem.org/Team:USTC_CHINA/Parts"